Please assess the completion status of the following clinical trial:

Trial Title: Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* DSM-IV diagnosis of schizophrenia, schizoaffective disorder (depressed type), or schizophreniform disorder~* First major episode of psychotic symptoms occurred within 2 years prior to study entry~* Participant in the UCLA Center for Neurocognition and Emotion in Schizophrenia~Exclusion Criteria:~* Neurological disorder or injury (e.g., encephalitis, epilepsy, traumatic brain injury)~* Mental retardation (e.g., premorbid IQ less than 70)~* Significant alcohol or substance abuse within 6 months prior to study entry~* Inability to complete research measures in English~* Any condition that may make risperidone use medically inadvisable

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Long-acting injectible risperidone (Type: EXPERIMENTAL): Participants who are randomly assigned to this arm will be administered the long-acting injectible form of risperidone (Risperdal Consta) every two weeks, plus group skills training and case management, for 12 months.
- Oral risperidone (Type: ACTIVE_COMPARATOR): Participants who are randomly assigned to this arm will be treated with the oral version of risperidone (Risperdal) daily, plus group skills training and case management, for 12 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).